Literature DB >> 31738206

Ovarian Cancer Genetics and Implications for Imaging and Therapy.

Sherif B Elsherif1,2, Silvana C Faria1, Chandana Lall2, Revathy Iyer1, Priya R Bhosale1.   

Abstract

Ovarian cancer is the second most common gynecologic malignancy in the United States. Ovarian cancer has a dismal prognosis when diagnosed at an advanced stage. Therapy for these cancers is determined not only by stage but also by their heterogeneous pathologic features, genetic mutations, and biology. In this review, we will discuss types of epithelial ovarian cancer, and their associated genetic mutations and the implications for imaging and treatment.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31738206     DOI: 10.1097/RCT.0000000000000932

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  6 in total

1.  The Value of Magnetic Resonance Diffusion-Weighted Imaging and Dynamic Contrast Enhancement in the Diagnosis and Prognosis of Treatment Response in Patients with Epithelial Serous Ovarian Cancer.

Authors:  Pawel Derlatka; Laretta Grabowska-Derlatka; Marta Halaburda-Rola; Wojciech Szeszkowski; Krzysztof Czajkowski
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

Review 2.  Current update on malignant epithelial ovarian tumors.

Authors:  Sherif B Elsherif; Priya R Bhosale; Chandana Lall; Christine O Menias; Malak Itani; Kristina A Butler; Dhakshinamoorthy Ganeshan
Journal:  Abdom Radiol (NY)       Date:  2021-06-05

3.  Comprehensive Analysis of Tumor Microenvironment Identified Prognostic Immune-Related Gene Signature in Ovarian Cancer.

Authors:  Na Li; Biao Li; Xianquan Zhan
Journal:  Front Genet       Date:  2021-02-10       Impact factor: 4.599

4.  Circ_0078607 inhibits the progression of ovarian cancer via regulating the miR-32-5p/SIK1 network.

Authors:  Yangqiu Jin; Hui Wang
Journal:  J Ovarian Res       Date:  2022-01-04       Impact factor: 4.234

5.  Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients.

Authors:  Dimitra Stergiopoulou; Athina Markou; Lydia Giannopoulou; Paul Buderath; Ioanna Balgkouranidou; Nikolaos Xenidis; Stylianos Kakolyris; Sabine Kasimir-Bauer; Evi Lianidou
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

6.  METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.

Authors:  Xuehan Bi; Xiao Lv; Dajiang Liu; Hongtao Guo; Guang Yao; Lijuan Wang; Xiaolei Liang; Yongxiu Yang
Journal:  Cancer Gene Ther       Date:  2020-09-16       Impact factor: 5.987

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.